Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I, Repeat Dose-Escalation Study of ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

NCT00056537 is registered in ClinicalTrials.gov with Active Biotech AB as lead sponsor.

NCT NCT00056537
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00056537 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I, Repeat Dose-Escalation Study of ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
Lead sponsor
Active Biotech AB
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2003
Completion date
December 31, 2006
Enrollment
44 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma, pancreatic cancer, renal cell carcinoma